Abstract
Bifidobacteria can potentially be used for gene therapy. Here, we reported that 65% of the total hIFN-α2b produced from Bifidobacteria longum transformed with pBAD-SPIFN plasmids encoding a fusion protein of the arabinosidase signal peptide and human IFN-α2b (hIFN-α2b), was secreted. For B. longum transformed with pBAD-IFN plasmids (hIFN-α2b without the signal peptide), only 15% of the total IFN-α2b was secreted and western blotting and N-terminal amino-acid sequence analysis revealed cleavage of the arabinosidase signal peptide from the secreted hIFN-α2b. Moreover, the active level of the secreted hIFN-α2b in the supernatant of B. longum transformed with pBAD-SPIFN plasmids was over 1,000 IU/ml commercial rhIFN-α2b. Hence, the arabinosidase signal peptide can enhance the secretion efficiency of IFN-α2b from B. longum.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Alvarez-Martín P, O’Connell-Motherway M, van Sinderen D, Mayo B (2007) Functional analysis of the pBC1 replicon from Bifidobacterium catenulatum L48. Appl Microbiol Biotechnol 76:1395–1402
Brod SA, Scott M, Burns DK, Phillips JT (1995) Modification of acute experimental autoimmune encephalomyelitis in the Lewis rat by oral administration of type 1 interferons. J Interferon Cytokine Res 15:115–122
Cani PD, Neyrinck AM, Fava F, Knauf C, Burcelin RG, Tuohy KM, Gibson GR, Delzenne NM (2007) Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia 50:2374–2383
Commane DM, Shortt CT, Silvi S et al (2005) Effects of fermentation products of pro- and prebiotics on trans-epithelial electrical resistance in an in vitro model of the colon. Nutr Cancer 51:102–109
Cronin M, Knobel M, O’Connell-Motherway M, Cresci A, Hughes RM, Rowland IR (2007) Molecular dissection of a bifidobacterial replicon. Appl Environ Microbiol 73:7858–7866
François C, Bernard I, Castelain S, Charleston B, Fray MD, Capiod JC, Duverlie G (2005) Quantification of different human alpha interferon subtypes and pegylated interferon activities by measuring MxA promoter activation. Antimicrob Agents Chemother 49:3770–3775
Fu GF, Li X, Hou YY, Fan YR, Liu WH, Xu GX (2005) Bifidobacterium longum as an oral delivery system of endostatin for gene therapy on solid liver cancer. Cancer Gene Ther 12:133–140
Fujimori M, Amano J, Taniguchi S (2002) The genus Bifidobacterium for cancer gene therapy. Curr Opin Drug Discov Devel 5:200–203
Horisberger MA, McMaster GK, Zeller H, Wathelet MG, Dellis J, Content J (1990) Cloning and sequence analysis of cDNAs for interferon- and virus-induced human Mx proteins reveal that they contain putative guanine nucleotide-binding sites: functional study of the corresponding gene promoter. J Virol 64:1171–1181
Kimura NT, Taniguchi S, Aoki K, Baba T (1980) Selective localization and growth of Bifidobacterium longum in mouse tumors following intravenous administration. Cancer Res 40:2061–2068
Le Loir Y, Gruss A, Ehrlich SD, Langella P (1998) A nine-residue synthetic propeptide enhances secretion efficiency of heterologous proteins in Lactococcus lactis. J Bacteriol 180:1895–1903
Li X, Fu GF, Fan YR, Liu WH, Liu XJ, Wang JJ, Xu GX (2003) Bifidobacterium adolescentis as a delivery system of endostatin for cancer gene therapy: selective inhibitor of angiogenesis and hypoxic tumor growth. Cancer Gene Ther 10:105–111
Reyes Escogido ML, De León Rodríguez A, Barba de la Rosa AP (2007) A novel binary expression vector for production of human IL-10 in Escherichia coli and Bifidobacterium longum. Biotechnol Lett 29:1249–1253
Ruuth K, Berglund A, Munoz V, Lundgren E (2007) Differential resistance of melanoma cells to treatment with recombinant IFN-alpha2b and leukocyte IFN. Anticancer Res 27:2109–2114
Scholz-Ahrens KE, Ade P, Marten B, Weber P, Timm W, Açil Y, Glüer CC, Schrezenmeir J (2007) Prebiotics, probiotics, and synbiotics affect mineral absorption, bone mineral content, and bone structure. J Nutr 137:838S–846S
Shiozawa S, Tanaka Y, Shiozawa K (1998) Single-blinded controlled trial of low-dose oral IFN-a for the treatment of xerostomia in patients with Sjögren’s syndrome. J Interferon Cytokine Res 18:255–262
Smilović V, Caserman S, Fonda I, Gaberc-Porekar V, Menart V (2008) A novel reporter gene assay for interferons based on CHO-K1 cells. J Immunol Methods 333:192–196
Tompkins WA (1999) Immunomodulation and therapeutic effects of the oral use of interferon-alpha: mechanism of action. J Interferon Cytokine Res 19:817–828
Tuohy KM, Rouzaud GC, Bruck WM, Gibson GR (2005) Modulation of the human gut microflora towards improved health using prebiotics-assessment of efficacy. Curr Pharm Des 11:75–90
Vassaux G, Nitcheu J, Jezzard S, Lemoine NR (2006) Bacterial gene therapy strategies. J Pathol 208:290–298
Wei MQ, Mengesha A, Good D, Anné J (2008) Bacterial targeted tumour therapy-dawn of a new era. Cancer Lett 259:16–27
Acknowledgments
We thank Yulin Liu, Department of Cellular Biology of Southern Medical University, for kind help of N-terminal amino-acids sequence analysis of hIFN-α2b. This work was supported by a grant from Shenzhen scientific Research Program of the People’s Republic of China (NO. 200801020).
Author information
Authors and Affiliations
Corresponding authors
Additional information
Communicated by Jorge Membrillo-Hernández.
Q. Deng, W. Zeng and Z. Yu contributed equally to this work.
Rights and permissions
About this article
Cite this article
Deng, Q., Zeng, W. & Yu, Z. Signal peptide of Arabinosidase enhances secretion of interferon-α2b protein by Bifidobacteria longum . Arch Microbiol 191, 681–686 (2009). https://doi.org/10.1007/s00203-009-0496-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00203-009-0496-5